Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹324 Cr
up ₹15 Cr vs Nov 2015
- Stocks held
- 25
- up 2 vs Nov 2015
- Top 10 weight
- 69.0%
- of the portfolio in its ten largest
- Cash & debt
- 10.8%
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In December 2015 it disclosed 25 stocks worth ₹324 Cr, up ₹15 Cr from Nov 2015. Its largest positions were Sun Pharmaceutical Industries Limited (20.1%), Lupin Limited (11.0%), Dr. Reddy's Laboratories Limited (9.2%); the ten largest together made up 69.0% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 88.6% of its equity. Cash and debt stood at 10.8%. Compared with Nov 2015 the fund entered 2 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
93%
Top-10 weight is higher than 93% of peers
Breadth
8%
Holds more stocks than 8% of peers
Cash
96%
Holds more cash than 96% of peers
What these mean: concentration · cash
Holdings in December 2015
Download CSVEvery line the fund disclosed, with the change against Nov 2015. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 20.11% | up 1.35 pts | ₹65.2 Cr | up ₹7.2 Cr | Added |
| Lupin Limited | 11.01% | down 0.22 pts | ₹35.7 Cr | up ₹98 L | Added |
| Cash, TREPS & receivables | 10.77% | down 1.83 pts | ₹34.9 Cr | down ₹4 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 9.24% | down 0.44 pts | ₹30 Cr | up ₹1 L | Held |
| Cipla Limited | 8.87% | down 0.34 pts | ₹28.8 Cr | up ₹27 L | Added |
| Divi's Laboratories Limited | 4.62% | down 0.20 pts | ₹15 Cr | up ₹6 L | Held |
| Aurobindo Pharma Limited | 4.09% | down 0.68 pts | ₹13.3 Cr | down ₹1.5 Cr | Trimmed |
| IPCA Laboratories Limited | 3.35% | down 0.39 pts | ₹10.9 Cr | down ₹71 L | Trimmed |
| Piramal Enterprises Limited | 2.70% | up 0.04 pts | ₹8.8 Cr | up ₹53 L | Added |
| Alkem Laboratories Limited | 2.55% | up 2.55 pts | ₹8.3 Cr | up ₹8.3 Cr | New |
| Sun Pharma Advanced Research Company Limited | 2.44% | down 0.15 pts | ₹7.9 Cr | down ₹10 L | Trimmed |
| Zydus Lifesciences Limited | 2.38% | down 0.67 pts | ₹7.7 Cr | down ₹1.7 Cr | Trimmed |
| Strides Pharma Science Limited | 2.21% | down 0.25 pts | ₹7.2 Cr | down ₹46 L | Trimmed |
| Pfizer Limited | 2.11% | down 0.21 pts | ₹6.8 Cr | down ₹33 L | Trimmed |
| Biocon Limited | 1.85% | up 0.12 pts | ₹6 Cr | up ₹65 L | Added |
| Sanofi India Limited | 1.58% | down 0.08 pts | ₹5.1 Cr | down ₹0 L | Held |
| EQ NARAYANA HRUDAYALAYA LTD | 1.57% | up 1.57 pts | ₹5.1 Cr | up ₹5.1 Cr | New |
| Unichem Laboratories Limited | 1.44% | down 0.15 pts | ₹4.7 Cr | down ₹24 L | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 1.30% | down 0.06 pts | ₹4.2 Cr | up ₹2 L | Added |
| Indraprastha Medical Corporation Limited | 1.28% | down 0.13 pts | ₹4.2 Cr | down ₹21 L | Trimmed |
| Syngene International Limited | 1.27% | up 0.13 pts | ₹4.1 Cr | up ₹60 L | Added |
| Natco Pharma Limited | 1.08% | up 0.05 pts | ₹3.5 Cr | up ₹31 L | Added |
| Torrent Pharmaceuticals Limited | 0.64% | down 0.02 pts | ₹2.1 Cr | up ₹4 L | Added |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.64% | up 0.01 pts | ₹2.1 Cr | up ₹14 L | Added |
| Shilpa Medicare Limited | 0.46% | up <0.01 pts | ₹1.5 Cr | up ₹8 L | Added |
| Indoco Remedies Limited | 0.45% | down 0.01 pts | ₹1.5 Cr | up ₹4 L | Added |
What changed, Nov 2015 to Dec 2015
New New positions (2)
- Alkem Laboratories Limited2.5% · ₹8.3 Cr
- EQ NARAYANA HRUDAYALAYA LTD1.6% · ₹5.1 Cr
Exited Exited (0)
None.
Added Biggest additions
- Sun Pharmaceutical Industries Limitedup ₹7.2 Cr (+1.35% pts)
- Lupin Limitedup ₹98 L (−0.22% pts)
- Biocon Limitedup ₹65 L (+0.12% pts)
- Syngene International Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Nov 2015, the weight rose most in Pharmaceuticals & Biotechnology (+0.4 pts), and fell most in Pharmaceuticals (−0.5 pts).
- Pharmaceuticals & Biotechnology88.2% → 88.6%+0.4 pts
- Pharmaceuticals5.9% → 5.4%−0.5 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Dec 2014 | Jun 2015 | Sep 2015 | Nov 2015 | Dec 2015 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 86.3% | 93.2% | 91.7% | 88.2% | 88.6% |
| Pharmaceuticals | 12.6% | 5.7% | 5.6% | 5.9% | 5.4% |
| Finance | 1.1% | 1.0% | 1.7% | 3.0% | 3.1% |
| Healthcare Services | — | — | 1.1% | 2.9% | 2.9% |
Allocation in Dec 2015change vs Nov 2015
- Pharmaceuticals & Biotechnology (17)88.6%▲ 0.4 pts
- Pharmaceuticals (4)5.4%▼ 0.5 pts
- Finance (1)3.1%
- Healthcare Services (2)2.9%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Dec 2015
10.8%
▼ 1.8 pts vs Nov 2015
- Cash alone
- 10.8%
- cash and net receivables
- A year earlier
- 6.3%
- Dec 2014 · now ▲ 4.5 pts
- Last 12 months
- 5.3% – 12.6%
- lowest to highest · record 12.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.